Liminatus Pharma, Inc.
$0.22
▲
2.34%
2026-04-21 07:54:00
liminatuspharma.com
NGM: LIMN
Explore Liminatus Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.83 M
Current Price
$0.22
52W High / Low
$33.66 / $0.16
Stock P/E
—
Book Value
$-0.06
Dividend Yield
—
ROCE
30.51%
ROE
—
Face Value
—
EPS
$-0.43
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1
Beta
0.63
Debt / Equity
—
Current Ratio
0.05
Quick Ratio
0.05
Forward P/E
—
Price / Sales
—
Enterprise Value
$9.52 M
EV / EBITDA
-3.21
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 2. | Assembly Biosciences, Inc. | $28.13 | — | $446.22 M | — | -5.8% | -5.1% | $39.7 / $9.68 | $13.04 |
| 3. | Revelation Biosciences, Inc. | $1.16 | — | $4.32 M | — | -94.64% | -1.31% | $43.48 / $0.99 | $5.59 |
| 4. | Codexis, Inc. | $2.62 | — | $235.35 M | — | -31.3% | -74.88% | $3.87 / $0.96 | $0.56 |
| 5. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
| 6. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 7. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.88 M | -0.7 M | -0 M | -0.17 M | -0.54 M |
| Net Profit | -8.17 M | -1.82 M | -0 M | -0.23 M | -0.6 M |
| EPS in Rs | -0.18 | -0.04 | -0 | -0.01 | -0.01 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -2.97 M | -3.33 M | -4.82 M | -2.71 M |
| Net Profit | -10.21 M | -3.55 M | -4.98 M | -2.93 M |
| EPS in Rs | -0.23 | -0.08 | -0.11 | -0.07 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 0.51 M | 5.41 M | 2.24 M | 6.84 M |
| Total Liabilities | 10.33 M | 24.75 M | 18.04 M | 17.65 M |
| Equity | -9.81 M | -19.34 M | 0 M | 0 M |
| Current Assets | 0.5 M | 5.28 M | 2.24 M | 6.84 M |
| Current Liabilities | 10.3 M | 24.75 M | 18.04 M | 17.65 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.96 M | -1.45 M | -3.35 M | -0.87 M |
| Investing CF | -0.79 M | -2.85 M | -0.82 M | 0 M |
| Financing CF | 11.03 M | 3.92 M | -0.45 M | 5.92 M |
| Free CF | -9.98 M | -1.45 M | -3.35 M | -0.87 M |
| Capex | -0.01 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -187.81% | 28.85% | -70.22% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.